ArticleAdvances in experimental medicine and biology2023
Understanding Ischemic Retinopathies: The Role of Succinate and Its Receptor in Retinal Pigment Epithelium.
Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Diosmetin alleviates retinal ischemia-reperfusion injury through SIRT1-mediated suppression of oxidative stress, inflammation, and PANoptosis.Immunologic research · 2026Article
- Cellular succinate metabolism and signaling in inflammation: implications for therapeutic intervention.Frontiers in immunology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinopathy is the general name for all condition of the eyes in which blood vessels that supply oxygen to the retina are damaged. These include diabetic retinopathy, retinopathy of prematurity, hypertensive retinopathy, and arteriosclerotic retinopathy. Although the initial trigger that leads to insufficient perfusion of the retina may be different, once a critical level of ischemia is achieved, all types of retinopathies seem to follow a common sequence-oxidative stress, followed by hypoxia-induced formation of morphologically abnormal vessels. This preretinal vascular growth is the most severe aspect of the retinopathy, as the outcome is often retinal detachment and eventually blindness. Regardless of which therapy strategy is followed, a deeper understanding of both normal retinal growth and the underlying molecular mechanisms of retinopathies is needed in order to come up with more effective therapies. This chapter focuses on the citric acid cycle intermediate succinate and its G protein-coupled receptor SUCNR1 in ischemic retinopathies, which were identified as potent mediators of vessel growth in the settings of both normal retinal development and proliferative ischemic retinopathies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.